What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?  

The clinical information provided is extremely limited (number of neoadjuvant cycles given, node-negative versus node-positive, RCB, toxicity, comorbidities) to provide a definitive recommendation. Therefore, to continue on current therapy or transition her to ado-trastuzumab, T-DM1, and anastrozole...

I agree with Dr. @Valero that the available information is extremely limited. Was the decision to avoid neoadjuvant chemotherapy based solely on age, or were other comorbidities or functional status considerations involved? If she were not a candidate for standard chemotherapy, it is likely that she...